WO2023170475 - USES AND METHODS FOR IL-2, IL-13, AND IL-4 CYTOKINE BIFUNCTIONAL MOLECULES
National phase entry:
Publication Number
WO/2023/170475
Publication Date
14.09.2023
International Application No.
PCT/IB2023/000132
International Filing Date
08.03.2023
Title **
[English]
USES AND METHODS FOR IL-2, IL-13, AND IL-4 CYTOKINE BIFUNCTIONAL MOLECULES
[French]
UTILISATIONS ET PROCÉDÉS POUR MOLÉCULES BIFONCTIONNELLES DE CYTOKINE D'IL-2, D'IL-13 ET D'IL-4
Applicants **
MEDICENNA THERAPEUTICS, INC.
Inventors
MERCHANT, Fahar
Priority Data
63/317,876
08.03.2022
US
63/328,689
07.04.2022
US
63/375,132
09.09.2022
US
63/375,299
12.09.2022
US
63/381,072
26.10.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7924 | |
| EPO | Filing, Examination, Granting | 77349 | |
| Japan | Filing, Examination, Granting | 4177 | |
| South Korea | Filing, Examination, Granting | 6233 | |
| USA | Filing, Examination, Granting | 29890 |
Total:
125,573
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Human interleukin-2 (IL-2), Human interleukin-13 (IL-13), and/or Human interleukin-4 (IL-4) cytokine fusions are provided. In particular, provided are IL-2, IL-4, and/or IL-13 cytokine fusions for use in monotherapeutic applications as well as in combination therapies for the treatment of cancer. Also provided are pharmaceutical compositions that include such IL-2 IL-4, and/or IL-13 cytokine fusions.[French]
L'invention concerne les fusion de cytokines d'interleukine 2 humaine (IL-2), d'interleukine 13 humaine (IL-13) et/ou d'interleukine 4 (IL-4) humaine. En particulier, l'invention concerne des fusions de cytokines d'IL-2, d'IL-4 et/ou d'IL-13 destinées à être utilisées dans des applications monothérapeutiques ainsi que dans des polythérapies pour le traitement du cancer. L'invention concerne également des compositions pharmaceutiques qui comprennent de telles fusions de cytokines d'IL-2, d'IL-4 et/ou d'IL-13.